RNA Atrium Therapeutics, Inc.

CIK 0002093101 7 ready 8-Ks latest October 9, 2026, 6:17 AM ET RSS · JSON

Activity: NORMAL 2 filings / 30d vs 1 baseline

Ready 8-Ks 7

Latest filing October 9, 2026, 6:17 AM ET

Top materiality 0.75

Event mix other_material ×4 · earnings ×2 · regulatory ×1

Sentiment 2 pos · 0 neg · 5 neu

Recent 8-K filings for RNA

Highest-materiality recent filing

Atrium Therapeutics Q2 2026: IND cleared for ATR 1072, BMS milestone $15M, cash $263.9M

August 13, 2026, 4:50 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

FDA cleared IND for ATR 1072; Corventis Phase 1/2 trial in PRKAG2 syndrome launched, ~37 participants planned.
Earned second BMS milestone payment of $15M in August, to be recognized in Q3 2026.

Read filing →

October 9, 2026, 6:17 AM ET other material materiality 0.20 neutral item 8.01

Atrium Therapeutics corrects post-PIPE share count to 21,571,507, including make-whole spin-off shares

PIPE securities purchase agreement dated Oct. 7, 2026 with accredited investors covers 5,170,384 common shares plus pre-funded warrants for up to 1,134,930 shares.
October 8, 2026, 6:52 AM ET other material materiality 0.60 neutral item 1.01 item 3.02 item 8.01 item 9.01

Atrium Therapeutics raises $50M PIPE at $7.93/share, extending cash runway through 2028

PIPE priced at-the-market: 5,170,384 shares at $7.93 plus pre-funded warrants for 1,134,930 shares at $7.929 each (exercise price $0.001); gross proceeds ~$50M.
August 13, 2026, 4:50 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

Atrium Therapeutics Q2 2026: IND cleared for ATR 1072, BMS milestone $15M, cash $263.9M

FDA cleared IND for ATR 1072; Corventis Phase 1/2 trial in PRKAG2 syndrome launched, ~37 participants planned.
July 14, 2026, 5:14 PM ET regulatory materiality 0.65 positive item 8.01 item 9.01

Atrium Therapeutics receives FDA IND clearance for ATR 1072 in PRKAG2 syndrome; Phase 1/2 trial to start

FDA cleared IND for ATR 1072, a precision cardiology RNA therapeutic for PRKAG2 syndrome.
May 14, 2026, 4:50 PM ET earnings materiality 0.55 neutral item 2.02 item 9.01 ◈ Earnings Releases

Atrium Therapeutics reports Q1 collaboration revenue $19.6M, driven by $15M BMS milestone; cash $267.8M

Collaboration revenue $19.6M in Q1 2026, primarily a $15M milestone from BMS partnership.
February 27, 2026, 6:59 PM ET other material materiality 0.75 neutral item 1.01 item 5.01 item 5.02 item 9.01 ◈ Material Agreements ×2◈ M&A Transactions

Atrium Therapeutics completes spin-off from Avidity; begins trading under RNA on Nasdaq

Separation of Atrium Therapeutics (SpinCo) from Avidity effective Feb 26, 2026; one SpinCo share for every ten Avidity shares distributed.
February 26, 2026, 6:59 PM ET other material materiality 0.75 neutral item 7.01 item 9.01

Atrium Therapeutics completes spin-off from Avidity; 15.5M shares distributed, trading begins Feb 27 under RNA

Avidity distributed 15,514,966 Atrium shares at a ratio of 1 share per 10 Avidity shares; holds no equity interest after.

Materiality & sentiment trend

Max materiality 0.75 · Median 0.65 · Most common event other_material

2 positive 0 negative 5 neutral

source · RNA on sec.gov